Other Events ·
NCI awards $2.9M grant to University of Oklahoma for clinical trials of RedHill's opaganib and CAR T-cell therapy
RDHLRedHill Biopharma Ltd.
The National Cancer Institute awarded a five-year, $2.9 million grant to the University of Oklahoma to conduct Phase 1b and Phase 2 clinical trials evaluating the combination of opaganib and CAR T-cell therapy for ultra-high-risk multiple myeloma. The funding supports safety and dosage assessments in up to 18 patients, followed by an effectiveness study enrolling up to 21 additional participants. RedHill will supply the investigational drug, while Lentigen Technology provides manufacturing support. RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology.